SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rally is drawing attention after Morgan Stanley named it a top pick, citing AWS growth and AI opportunities. Traders are broadly bullish, though some question whether the move can hold and point to earnings and technical resistance as potential tests.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgraded CoreWeave to Buy while lowering its price target, drawing attention after a sharp selloff in AI infrastructure stocks. Traders debated whether the upgrade and AI demand could support a rebound or whether heavy debt and financing concerns would keep pressure on the shares.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBios expanded FDA approval of ANKTIVA for papillary-only BCG-unresponsive bladder cancer, alongside long-term Phase 3 data showing durable responses and cystectomy avoidance, is driving attention. Traders are frustrated by the share-price drop despite the positive developments, debating a sell-the-news reaction and broader biotech weakness versus unverified claims of short-selling pressure.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Better-than-expected third-quarter results and a substantially more upbeat 2027 earnings outlook are driving CLF attention and a sharp rally. Traders are debating whether the forecast and steel-price tailwinds can overcome debt and execution concerns, while some view the move as vulnerable to profit-taking or short-covering volatility.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are drawing attention after a sharp slide and technical breakdown, with traders repeatedly pointing to insider share sales as added selling pressure. Some view the sales as planned and the decline as disconnected from the companys growth, while others worry about management confidence and cite broader Southeast Asian market and oil-related risks.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine is surging after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, strengthening the companys path toward an FDA resubmission. Traders are broadly bullish and debating a possible short squeeze, while some cite dizziness concerns and potential profit-taking.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

CBRS is drawing attention amid a steep post-IPO selloff, with traders pointing to successive insider-share unlocks and a broader AI and semiconductor pullback. Bears cite the companys high valuation, scaling concerns and OpenAI dependence, while bulls argue the decline is overdone and are buying dips.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

Almontys investor-day webcast is driving concern, with traders criticizing CEO Lewis Blacks presentation and questioning whether it signaled an undisclosed problem. Others say the content sounded positive and see no clear negative update, leaving the selloffs cause uncertain.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

Traders are focused on AEP and X-energy evaluating a potential 960-MW small modular reactor project in Indiana, with Amazon funding development and potentially buying power long termfueling optimism about nuclear power for data centers. The project remains at the evaluation stage, and enthusiasm over the opportunity is tempered by concern about XEs sharp selloff and the long path to commercial deployment.

Dynex Capital, Inc. is an internally managed mortgage real estate investment trust. It engages in the business of investing in mortgage-backed securities. The company was founded on December 18, 1987 and is headquartered in Glen Allen, VA.

Dynex Capital, Inc.

Dynexs Q3 results have focused attention on a sharp book-value decline as wider agency mortgage spreads drove losses, alongside earnings below the dividend payout. Traders are split between buying the dip on managements confidence in liquidity and future spread recovery, and worrying about dividend coverage and further share-price downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Huge Narratives and Market Moments

The Market is once again producing the kind of outsized news that can quickly turn obscure names into market-watchlist favorites. Kraig Biocraft Laboratories (OTCQB:KBLB), HCW Biologics (NASDAQ:HCWB), Uxin (NASDAQ:UXIN), Green Circle Decarbonize Technology (NYSEAMERICAN:GCDT), Powell Max Limited (NASDAQ: PMAX), Netcapital (NASDAQ:NCPL), STAK Inc. (NASDAQ:STAK), and Wetour Robotics (NASDAQ:WETO) are each tied to different narratives.

HCW Biologics Commences 1-for-6 Reverse Stock Split

(RTTNews) - HCW Biologics Inc. (HCWB), a clinical-stage biopharmaceutical company, Friday announced that it has been approved for a 1-for-6 reverse stock split of the company's common stock, with par value of $0.0001, effective June 30...

Microcap HCW Biologics' Therapy Shows Early Promise Against Autoimmune Hair Loss

HCW Biologics reports positive Phase 1 data for HCW9302, with all 2nd-cohort alopecia patients showing a clinical response.read more...

Why Is HCW Biologics Stock Surging On Friday?

HCW Biologics Inc. (NASDAQ: HCWB) stock rallies on Friday as a $4 million private placement offering boosts liquidity for its clinical trials.read more...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

Why HCW Biologics Stock Is Surging On Thursday?

HCW Biologics Inc. (NASDAQ:HCWB) stock is rallying after securing a $4 million private placement to fund its clinical pipeline. Read the full market breakdown.read more...

Biotech and Biologics Break Out: These Tiny Stocks Are Suddenly Dominating the Market Conversation

Emerging biotech and biologics names exploded onto traders’ radar Wednesday as a wave of clinical milestones, regulatory momentum, strategic acquisitions, and high-volume technical breakouts fueled aggressive speculation across the sector. $HCWB, $TGNT, $KBLB, $SLS, $RKDA, $ROIV, $SLXN

Why HCW Biologics Stock Is Falling On Tuesday?

HCW Biologics Inc. (NASDAQ: HCWB) stock falls on Tuesday. Retail traders lock in gains after a 262% surge driven by Q1 earnings and pipeline updates.read more...

What's Going On With HCW Biologics Stock Monday?

HCW Biologics (HCWB) reports Q1 EPS of $0.37 and $6.54M in sales. Find out why the stock skyrocketed and what's next.read more...

Clinical-Stage Biopharma Surges on Profit Swing and Imminent Phase 1 Data Readout

The market for autoimmune disease therapies is being reshaped by a new generation of biologics targeting regulatory T cells, the immune system's own braking mechanism. Alopecia areata, an autoimmune disorder that causes patchy or complete hair loss, affects millions worldwide and has only recently received its first FDA-approved oral therapies, each carrying significant tolerability concerns. Developers chasing safer, more selective alternatives have made Treg-expanding approaches one of the most closely watched corners of clinical-stage immunology.Shares of HCW Biologics Inc. (Nasdaq: ...

• Reported GAAP EPS of -$11.58 up 71.58% YoY
• Reported revenue of $0.14M up 1969.74% YoY

HCW Biologics faces substantial going concern risks, significantly increased quarterly net losses, and operational difficulties in manufacturing reagents for the CAR-T therapy market that may impede future business growth.

HCW Biologics demonstrated preliminary clinical efficacy for its lead autoimmune candidate, re-acquired commercial-ready reagent rights to support future partnerships, and remains on track for upcoming T-cell engager clinical trials.

HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.

HCW Biologics Inc

HCWB Stock Soars Pre-Market On Positive Research Results For CAR-T Cell Therapy

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.</li><li>The company said that CAR-Ts produced with its reagent are highly enriched in long-lived T memory stem cells.</li><li>HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.</li></ul>HCW Biologics Inc. (HCWB) shares soared more than 56% in Monday’s pre-market trade after the company announced positive research results for its CAR-T cell therapy.HCW Biologics stated that HCW9206, its proprietary, commercial-stage multi-cytokine fusion protein reagent, provides a new approach to generate CAR-T cells for immunotherapy with increased function at a cost-effective price.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/HCWB">HCW Biologics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels.<h2 class="st-heading-2">HCW9206 CAR-Ts Outperform Standard Methods, Says Company</h2>HCW Biologics stated that CAR-T cells manufactured with HCW9206 were significantly superior to those manufactured with standard methods.The company said that CAR-Ts produced using its reagent are highly enriched in long-lived T-memory stem cells. HCW Biologics added that these CAR-Ts also displayed potent activity across distinct disease experimental models, namely, HIV-1 or B-cell leukemia.“Based on experimental models, HCW9206 has shown improvement in functional activities and persistence of CAR-Ts following adoptive transfer, a goal the industry has been trying to achieve for the last decade,” said HCW Biologics CEO, Dr. Hing C. Wong.The company stated that in its study, HCW9206 helped generate long-lasting duoCAR-T cells that showed strong HIV suppression in humanized mouse models using T cells from people living with HIV. The approach could extend CAR-T therapy durability and support efforts toward a functional HIV cure, it added.<h2 class="st-heading-2">Why Are CAR-T Cells Important?</h2>CAR-T cells represent a new way to treat cancer using the patient’s own immune system. These cells genetically modify a patient’s T cells so they can recognize and attack specific cancer cells, reducing damage to healthy tissue compared with traditional treatments.Additionally, once CAR-T cells are modified and infused into a patient’s body, they multiply and continue to fight cancer.<a href="https://stocktwits.com/symbol/HCWB">HCWB stock</a> is down 47% year-to-date and 96% over the past 12 months. The Vanguard Extended Market Index Fund ETF Shares (VXF) is up 20% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/soc-stock-soars-after-sable-resumes-oil-flow-from-california-pipeline/cZ32wB1RIfi">SOC Stock Rises Pre-Market After Energy Secretary Order Restarts Sable’s California Oil Pipeline</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HCW Biologics said its proprietary multi-cytokine fusion protein reagent, HCW9206, offers a cost-effective way to generate higher-function CAR-T cells for immunotherapy.

Vanguard Extended Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1.26
Prev Close	$1.24
Open	$1.24
Dividend Yield	0.00%
50-Day Moving Average	$2.24
Beta	0.53
Avg. Volume	918,103.63
PE Ratio	-0.04

52-Week High	$25.44
52-Week Low	$1.14
Market Capitalization	$2.77M
EPS (Annual)	-$63.78
Price to Book	0.27
Revenue Per Employee	$1,549.49

Feed

News

Sentiment

Earnings

Fundamentals

Info

HCWB Fundamentals